Drugs / REMIDEVIR
REMIDEVIR
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 19 trials | ||||||
| Phase 1 | NCT06328400 | Mar → May 2024 | respiratory syncytial virus infectious disease | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT06005714 | Aug → Oct 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06093230 | Jul → Aug 2023 | liver disorder | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT06093308 | Jul → Aug 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05932459 | Jul → Sep 2023 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05895812 | May → Aug 2023 | — | Shanghai Vinnerna Biosciences Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05221138 | Dec 2021 → Jan 2022 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05201690 | Dec 2021 → Jan 2022 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 1 | NCT05227768 | Nov 2021 → Jan 2022 | — | Vigonvita Life Sciences | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06206720 | Jan 2024 → Jun 2025 | respiratory syncytial virus infectious disease | Vigonvita Life Sciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-01-10 | Shanghai Junshi Bioscience Co., Ltd. | Regulatory 君实生物宣布民得维®治疗新冠获常规批准 junshipharma.com ↗
北京时间2025年1月10日，君实生物（1877.HK，688180.SH）宣布，公司旗下的口服核苷类抗新型冠状病毒（SARS-CoV-2）药物民得维 ® （氢溴酸氘瑞米德韦片，产品代号：VV116/JT001）用于治疗轻中度新型冠状病毒感染（COVID-19）的成年患者的适应症正式获得国家药品监督管理局（NMPA）同意，由附条件批准转为常规批准。 |
| 2023-12-13 | Shanghai Junshi Bioscience Co., Ltd. | Regulatory 君实生物宣布拓益 ® 3项新增适应症、民得维 ® 纳入新版国家医保目录 junshipharma.com ↗
公司两款创新药产品成功纳入《国家基本医疗保险、工伤保险和生育保险药品目录（2023年）》（国家医保目录），其中拓益 ® （特瑞普利单抗注射液）新增3项适应症，民得维 ® （氢溴酸氘瑞米德韦片，产品代号：VV116/JT001）为首次纳入正式医保目录。 |
| 2023-11-23 | Shanghai Junshi Bioscience Co., Ltd. | Results 君实生物新冠口服药民得维 ® 第2项三期研究结果荣登《柳叶刀-感染病学》 junshipharma.com ↗
北京时间2023年11月23日，国际感染病学期刊排名第一的《柳叶刀-感染病学》（ The Lancet Infectious Diseases ，影响因子：56.3）发布了国产新冠口服药民得维 ® （氢溴酸氘瑞米德韦片，产品代号：VV116/JT001）的一项Ⅲ期临床研究的完整数据。 |
| 2023-01-29 | Shanghai Junshi Bioscience Co., Ltd. | Regulatory 君实生物宣布口服抗新冠病毒药物民得维®（VV116）获得国家药品监督管理局批准 junshipharma.com ↗
北京时间2023年1月29日，君实生物（1877.HK，688180.SH）宣布，公司旗下的口服核苷类抗新型冠状病毒（SARS-CoV-2）药物民得维 ® （氢溴酸氘瑞米德韦片，产品代号：VV116/JT001）获得国家药品监督管理局（NMPA）批准，用于治疗轻中度新型冠状病毒感染（COVID-19）的成年患者。 |
| 2022-12-29 | Shanghai Junshi Bioscience Co., Ltd. | Results 君实生物宣布《新英格兰医学杂志》发表口服抗新冠病毒药物VV116对比PAXLOVID治疗伴有高风险因素的轻/中度COVID-19患者III期临床研究结果 junshipharma.com ↗
结果显示，研究主要终点达到设计的非劣效终点，相比PAXLOVID，VV116组的临床恢复时间更短，安全性方面的顾虑更少。 |
| 2022-04-17 | Shanghai Junshi Bioscience Co., Ltd. | Results 君实生物口服抗新冠病毒药物VV116同时具有治疗呼吸道合胞病毒（RSV）感染的潜力 junshipharma.com ↗
研究发现，VV116在RSV多个敏感细胞系上具有优异的抗病毒效果。 |
| 2022-03-16 | Shanghai Junshi Bioscience Co., Ltd. | Results 君实生物口服抗新冠病毒药物VV116公布3项I期临床数据 junshipharma.com ↗
在安全性方面，VV116在健康受试者中显示出令人满意的安全性及耐受性。 |
All press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-01-10 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物宣布民得维®治疗新冠获常规批准 junshipharma.com ↗ |
| 2023-12-13 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物宣布拓益 ® 3项新增适应症、民得维 ® 纳入新版国家医保目录 junshipharma.com ↗ |
| 2023-11-23 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物新冠口服药民得维 ® 第2项三期研究结果荣登《柳叶刀-感染病学》 junshipharma.com ↗ |
| 2023-01-29 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物宣布口服抗新冠病毒药物民得维®（VV116）获得国家药品监督管理局批准 junshipharma.com ↗ |
| 2022-12-29 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物宣布《新英格兰医学杂志》发表口服抗新冠病毒药物VV116对比PAXLOVID治疗伴有高风险因素的轻/中度COVID-19患者III期临床研究结果 junshipharma.com ↗ |
| 2022-04-17 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物口服抗新冠病毒药物VV116同时具有治疗呼吸道合胞病毒（RSV）感染的潜力 junshipharma.com ↗ |
| 2022-03-16 | Shanghai Junshi Bioscience Co., Ltd. | 君实生物口服抗新冠病毒药物VV116公布3项I期临床数据 junshipharma.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REMIDEVIR | ChEMBL registry synonym — accepted as the source's own label CHEMBL4876167 ↗ |
| Known as | Deuremidevir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05895812 ↗ |
| Known as | Deuremidevir Hydrobromide | “Deuremidevir Hydrobromide for Suspension will be orally administered at the dosing levels of 15 mg/kg BID, 20 mg/kg BID, or 20 mg/kg TID for five days according to the weight...” NCT06206720 ↗ |
| Known as | Deuremidevir Hydrobromide for Suspension | “Deuremidevir Hydrobromide for Suspension 900mg, orally, Q12h, 5.5 days” NCT06328400 ↗ |
| Known as | Deuremidevir Hydrobromide Tablets | “Drug: Deuremidevir Hydrobromide Tablets” NCT05895812 ↗ |
| Known as | Mindeudesivir | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005714 ↗ |
| Known as | Mindvy | “VV116 (Mindvy, JT001) is a deuterated oral derivative of remdesivir hydrobromide developed for the treatment of COVID-19.” PMID 41733177 ↗ Feb 2026 |
| Known as | VV-116 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL4876167 ↗ |
| Known as | VV116 | “VV116 (Mindvy, JT001) is a deuterated oral derivative of remdesivir hydrobromide developed for the treatment of COVID-19.” PMID 41733177 ↗ Feb 2026 |
| Modality | Small molecule | — CHEMBL4876167 ↗ |
| Route | Oral | “Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;” NCT05201690 ↗ |